Handelsavisen
prelaunch
Companies ›Healthcare ›0858.HK
08
0858.HK — HKEX Pharmaceuticals

Extrawell Pharmaceutical Holdings Ltd

HK$0,07
Open in Charts → Attach watcher ⌖
— —
HKD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
214,6M HKD
P/E
1,0x
EV / Rev
—
Div yield
—
Op margin
—
ROE
—
Net margin
—
Debt / equity
—
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

Extrawell Pharmaceutical Holdings Ltd is a pharmaceutical company that develops and commercializes prescription drugs, primarily in the oncology and autoimmune disease treatment spaces.

Business. Extrawell Pharmaceutical Holdings Ltd (0858.HK) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Hong Kong and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data. Consequently, the company is described at the industry level within the broader healthcare and pharmaceuticals sector.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation→
1,0x
P/E
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability
—
not yet wired
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 0858.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 0858.HK. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Extrawell Pharmaceutical Holdings Ltd (0858.HK) is a pharmaceutical company engaged in the development and sale of pharmaceutical products. The firm is headquartered in Hong Kong and is primarily listed on the Hong Kong Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not disclosed in the available data. Consequently, the company is described at the industry level within the broader healthcare and pharmaceuticals sector.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    AI synthesis
    GENERATED
    — missing data
    Key takeaways
    • The company has a low level of dilution, with basic and diluted shares outstanding being equal.
    • Market capitalization is relatively small at HKD 223.3 million, with a market price of HKD 0.077 per share.
    • Liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
    • Profitability and return metrics are not available, limiting the ability to compare the company's performance against industry benchmarks.
    • Segments and geographic exposure are not disclosed, making it impossible to assess revenue concentration or geographic diversification.
    • Growth trajectory is unclear due to the absence of forward-looking guidance or historical performance data.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Annual
    ANNUALFiled 2023-06-29
    FY 2023 · Full-year highlights

    Revenue HK$72.6M, −1,8% YoY; Operating income +0,8% YoY.

    RevenueHK$72.6M−1,8 % YoY
    Operating incomeHK$150.4M+0,8 % YoY
    Net incomeHK$129.3M−1,0 % YoY
    Free cash flowHK$131.8M+1,3 % YoY
    EPS—
    Operating cash flowHK$1.2M+166,8 % YoY
    Financials
    Income statement
    RevenueHK$72.6M
    Gross profitHK$31.1M
    Operating incomeHK$150.4M
    Net incomeHK$129.3M
    Margins
    Gross margin42.9%
    Operating margin207.2%
    Net margin178.1%
    FCF margin181.6%
    Balance sheet
    Total assetsHK$1.44B
    Total liabilitiesHK$163.2M
    Total equityHK$1.28B
    Cash & equivalents—
    Long-term debtHK$103.2M
    Cash flow
    Operating cash flowHK$1.2M
    CapEx-HK$6.6M
    Free cash flowHK$131.8M
    SBC—
    P&L flow · revenue → net income
    Revenue HK$72.6MOperating costs HK$77.8MTax HK$21.1MNet income HK$129.3M
    Highlights
    • ▍Revenue HK$72.6M, −1,8% YoY
    • ▍Operating income +0,8% YoY
    • ▍Net income −1,0% YoY
    • ▍Free cash flow +1,3% YoY
    • ▍Net margin 178.1%

    Valuation FY

    Market price
    HK$0,07
    Market cap
    HK$223.3M
    Enterprise valueⓘ
    —
    P/Eⓘ
    1.0x
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    —
    Net cashⓘ
    —
    Current ratioⓘ
    —
    Debt / equityⓘ
    —
    ROAⓘ
    —
    ROEⓘ
    —
    Cash conversionⓘ
    —
    CapEx / revenueⓘ
    —
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskUnknown

    Benchmarks vs cohort

    No cohort benchmark data available for this issuer yet.

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    Source documents
    • Extrawell Pharmaceutical Holdings Ltd Market data — financials · 2026-05-26

    Ownership & reference

    Leadership

    • Yi GuoChief Executive Officer, Executive Director
    • Yi XieExecutive Chairman of the Board

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    0858.HKCanonical
    HKEX · HKD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskUnknown

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2023-06-29 20:20 UTCEARNINGSAnnual results — FY 2023 Revenue HKD 72.6M · Net HKD 129.3M
    2022-06-29 20:14 UTCEARNINGSAnnual results — FY 2022 Revenue HKD 73.9M · Net HKD 130.6M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage